


## Ginsenoside Rf

<b>Cat. No.:</b>	HY-N0601		
<b>CAS No.:</b>	52286-58-5		
<b>Molecular Formula:</b>	C <sub>42</sub> H <sub>72</sub> O <sub>14</sub>		
<b>Molecular Weight:</b>	801.01		
<b>Target:</b>	Calcium Channel; Endogenous Metabolite		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (124.84 mM; Need ultrasonic)  
 Ethanol : 50 mg/mL (62.42 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.2484 mL	6.2421 mL	12.4842 mL
	5 mM	0.2497 mL	1.2484 mL	2.4968 mL
	10 mM	0.1248 mL	0.6242 mL	1.2484 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits N-type Ca <sup>2+</sup> channel.
<b>IC<sub>50</sub> &amp; Target</b>	N-type calcium channel
<b>In Vitro</b>	Ginsenoside Rf is a saponin, which is present in only trace amounts within ginseng. At saturating concentrations, Ginsenoside Rf rapidly and reversibly inhibits N-type, and other high-threshold, Ca <sup>2+</sup> channels in rat sensory neurons to the same degree as a maximal dose of opioids. The effect is dose-dependent (half-maximal inhibition: 40 μM) and it is virtually eliminated by pretreatment of the neurons with pertussis toxin, an inhibitor of G(o) and Gi GTP-binding proteins. Ginsenoside Rf also inhibits Ca <sup>2+</sup> channels in the hybrid F-11 cell line <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Since inhibition of Ca <sup>2+</sup> channels in sensory neurons contributes to antinociception by opioids, analgesic actions of Ginsenoside Rf are tested. Dose-dependent antinociception is found by systemic administration of Ginsenoside Rf in mice using two separate assays of tonic pain: in the acetic acid abdominal constriction test, the ED <sub>50</sub> is 56±9 mg/kg, a concentration similar to those reported for aspirin and acetaminophen in the same assay; in the tonic phase of the biphasic formalin test, the ED <sub>50</sub> is 129±32 mg/kg <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal Administration <sup>[2]</sup>

Mice<sup>[2]</sup>

Naive, adult (7-12 week old) mice of outbred Swiss-Webster stock are used in all in vivo experiments. Mice are brought to a quiet testing room, and acclimated to table-top Plexiglas observation chambers (30 cm high; 30 cm diameter) for 30 min. They are then weighed and injected with Ginsenoside Rf (25, 50, or 75 mg/kg) or vehicle (preceded by naloxone or saline in one experiment). Twenty min later, a 0.9% solution of glacial acetic acid is injected intraperitoneally (i.p.) in a volume of 10 mL/kg. For the next 30 min, the number of constrictions (writhes)-strong contractions of the abdominal musculature accompanied by dorsoflexion of the back and extension of the hindlimbs-are counted and recorded in 5-min blocks. Four mice (one per chamber) are observed simultaneously by a single, experienced experimenter. To control for the considerable circadian and other environmental variance accompanying this nociceptive assay, two vehicle controls are tested alongside two Ginsenoside Rf-administered mice in every experimental session<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Nah SY, et al. A trace component of ginseng that inhibits Ca<sup>2+</sup> channels through a pertussis toxin-sensitive G protein. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8739-43.
- [2]. Mogil JS, et al. Ginsenoside Rf, a trace component of ginseng root, produces antinociception in mice. Brain Res. 1998 May 11;792(2):218-28.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA